ReachMD CME

CME credits: 0.25 Valid until: 02-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-HNSCC-Aligning-Teams-Transforming-Care/54394/ This activity reviews data from the KEYNOTE-689 and NIVOPOSTOP trials evaluating perioperative immune checkpoint inhibition in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). Experts examine trial design, efficac...

CME credits: 0.25 Valid until: 31-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-today-and-shaping-tomorrow-in-ism-personalized-strategies-with-current-and-emerging-kit-inhibitors/54388/ This online educational activity explores the evolving role of KIT-targeted tyrosine kinase inhibitors (TKIs) in indolent systemic mastocytosis (ISM). Expert faculty discuss pivotal c...

CME credits: 0.25 Valid until: 31-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/stuck-on-antihistamines-for-managing-patients-with-ckd-ap-time-to-reconsider/37607/ Despite effective and recommended therapies, many healthcare providers still consider antihistamines as the first-choice treatment for CKD-associated pruritus. Join Drs. Antoine Lanot and Gil Yosipovitch as they revi...

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/modern-obstructive-hcm-care-from-unmet-needs-to-individualized-myosin-inhibitor-therapy/56979/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoi...

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/safety-in-ohcm-therapy-how-and-when-to-transition-treatment/56831/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functi...

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing sy...

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongo...

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and func...

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/molecular-precision-how-myosin-inhibitors-redefine-control/54839/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functio...

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/when-blockers-fall-short-in-ohcm-time-for-a-new-approach/54838/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functiona...

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/cracking-the-code-of-obstruction-unmet-needs-in-ohcm/54837/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional li...

CME credits: 0.25 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-steroidal-mras-the-nonsteroidal-mra-lens-in-hf/49198/ In this brief podcast, Drs. Maria Pabon and Robert Mentz explore the evolving role of mineralocorticoid receptor antagonism in heart failure, with emphasis on patients who appear clinically stable yet remain at elevated biologic risk. They...

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/fcrn-same-class-different-pathsspot-agent-differentiators/54778/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools...

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-2-point-signal-apply-2-point-rule/54777/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, Q...

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/shared-goals-shared-gains-align-with-patient-preferences/54776/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—...

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/escalate-with-intention-stepwise-target-anchored-moves/54773/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—in...

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-igg-clock-redose-using-igg-kinetics/54772/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL,...

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/when-to-begin-fcrn-initiation-criteria-key-evidence/54771/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—inclu...

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/turning-flares-into-function-flag-uncontrolled-disease/54770/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—in...

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/minimal-by-design-define-mse-endpoints/54769/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL,...

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/target-locked-in-gmg-why-t2t-matters/54768/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QM...

CME credits: 1.00 Valid until: 05-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-voices-and-provider-partnerships-to-advance-cardio-kidney-metabolic-outcomes/56471/ Expert-curated slides on the fundamentals of cardio–kidney–metabolic (CKM) syndrome, emphasizing alignment of clinical guidelines with patient-centered care and strategies for identifying and addressing patie...

CME credits: 0.25 Valid until: 19-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/dka-new-consensus-practice/50979/ If widespread use of continuous ketone monitoring (CKM) devices is to be safe and effective in reducing the occurrence of diabetic ketoacidosis (DKA), it is important to establish clear ketone thresholds which notify CKM users when action on their part is required....

CME credits: 0.25 Valid until: 13-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/shifting-the-script-personalizing-overactive-bladder-treatment-in-complex-patients/54125/ This audio-only podcast examines where contemporary approaches fall short when managing overactive bladder (OAB) in patients with complex clinical considerations, including women with persistent symptoms and me...

CME credits: 0.25 Valid until: 13-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-selecting-therapy-cushing-syndrome/50063/ Cushing syndrome has seen exciting advances over the last couple of years, but how do they translate into improved patient care? Let’s dig into a couple of cases and discuss! =